S. Cebeci

Association of PET/CT-Derived Metabolic Parameters with Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: An Analysis Across Molecular Subtypes

Background: Pathological complete response (pCR) following neoadjuvant systemic therapy (NST) is associated with improved outcomes in breast cancer. We evaluated the association between PET/CT-derived metabolic parameters and pCR and explored whether these associations differed according to molecular subtype. Methods:...

Progression Patterns as Determinants of Post-Progression Survival in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors

In patients with HR+/HER2− metastatic breast cancer, the site of first progression after CDK4/6 inhibitor therapy may help estimate subsequent prognosis, and routinely available imaging findings may add practical value when assessing risk after CDK4/6 inhibitor failure.

Concordance between multidisciplinary tumor board decisions and AI-based recommendations in endometrial cancer: impact of discordance direction on clinical outcomes.